Immune Response Remune Trials To Continue After Agouron Drops Rights
Executive Summary
Immune Response Corporation will continue clinical trials for the HIV therapy Remune (HIV-1 immunogen) following the decision by Pfizer subsidiary Agouron to drop its rights to develop and market the product, IRC said July 6.
You may also be interested in...
Alkermes Cutbacks Play Well On Wall Street; Biotech Model In Down Market?
Alkermes' August rebound on Wall Street suggests that the less-is-more approach is playing well with investors
Alkermes Cutbacks Play Well On Wall Street; Biotech Model In Down Market?
Alkermes' August rebound on Wall Street suggests that the less-is-more approach is playing well with investors
Remune Virologic Response Data Is At Center Of Publication Dispute
The dispute between a University of California at San Francisco researcher and Immune Response over publication of results from a Remune study focuses on the presentation of virologic response data.